Ameriprise Financial Inc. Sells 244,102 Shares of Repligen Corporation $RGEN

Ameriprise Financial Inc. lessened its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 26.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 684,988 shares of the biotechnology company’s stock after selling 244,102 shares during the quarter. Ameriprise Financial Inc.’s holdings in Repligen were worth $87,160,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new position in Repligen during the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. bought a new position in Repligen during the fourth quarter worth about $40,000. Signaturefd LLC boosted its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. boosted its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 193 shares during the period. Finally, UMB Bank n.a. boosted its position in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 332 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada raised their price objective on shares of Repligen from $193.00 to $204.00 and gave the company an “outperform” rating in a research report on Wednesday, July 30th. Evercore ISI cut their price objective on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research report on Tuesday, July 8th. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. Finally, Barclays assumed coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $169.45.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company’s stock.

Repligen Trading Down 2.8%

RGEN stock opened at $121.26 on Tuesday. The company has a market capitalization of $6.82 billion, a PE ratio of -485.02, a price-to-earnings-growth ratio of 2.30 and a beta of 1.05. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company’s 50 day moving average price is $121.57 and its two-hundred day moving average price is $130.87. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.